Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data

In the Phase 3 ELOQUENT-2 trial, elotuzumab plus lenalidomide and dexamethasone (ELd) showed a 30% reduced risk of progression/death vs lenalidomide/dexamethasone and acceptable safety in patients (pts) with relapsed/refractory multiple myeloma (RRMM). However, therapies for pts refractory or intolerant to lenalidomide are needed. Pomalidomide has shown activity in lenalidomide-refractory pts and enhanced elotuzumab efficacy in a mouse model. Therefore, pomalidomide was combined with elotuzumab and dexamethasone (EPd) in this Phase 2 multicenter single-arm study (NCT02612779).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research